Outcomes after newborn screening for propionic and methylmalonic acidemia and homocystinurias
Journal of Inherited Metabolic Disease · 2024-07 · 47 (4) · 674-689
DOI: 10.1002/jimd.12731 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 02.04.2024. Verfasst von Anna T Reischl-Hajiabadi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Heidelberg University, Medical Faculty of Heidelberg, Center for Child and Adolescent Medicine, Division of Child Neurology and Metabolic Medicine, H…. Hauptthemen laut MEDLINE: Neonatal Screening, Homocystinuria, Amino Acid Metabolism, Inborn Errors, Propionic Acidemia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dietmar Hopp Stiftung.
Abstract (Originalsprache)
The current German newborn screening (NBS) panel includes 13 inherited metabolic diseases (IMDs). In addition, a NBS pilot study in Southwest Germany identifies individuals with propionic acidemia (PA), methylmalonic acidemia (MMA), combined and isolated remethylation disorders (e.g., cobalamin [cbl] C and methylenetetrahydrofolate reductase [MTHFR] deficiency), cystathionine β‐synthase (CBS) deficiency, and neonatal cbl deficiency through one multiple‐tier algorithm. The long‐term health benefits of screened individuals are evaluated in a multicenter observational study. Twenty seven screened individuals with IMDs (PA [ N = 13], MMA [ N = 6], cblC deficiency [ N = 5], MTHFR deficiency [ N = 2] and CBS deficiency [ N = 1]), and 42 with neonatal cbl deficiency were followed for a median of 3.6 years. Seventeen screened IMD patients (63%) experienced at least one metabolic decompensation, 14 of them neonatally and six even before the NBS report (PA, cbl‐nonresponsive MMA). Three PA patients died despite NBS and immediate treatment. Fifteen individuals (79%) with PA or MMA and all with cblC deficiency developed permanent, mostly neurological symptoms, while individuals with MTHFR, CBS, and neonatal cbl deficiency had a favorable clinical outcome. Utilizing a combined multiple‐tier algorithm, we demonstrate that NBS and specialized metabolic care result in substantial benefits for individuals with MTHFR deficiency, CBS deficiency, neonatal cbl deficiency, and to some extent, cbl‐responsive MMA and cblC deficiency. However, its advantage is less evident for individuals with PA and cbl‐nonresponsive MMA. Synopsis Early detection through newborn screening and subsequent specialized metabolic care improve clinical outcomes and survival in individuals with MTHFR deficiency and cystathionine‐β‐synthase deficiency, and to some extent in cobalamin‐responsive methylmalonic acidemia (MMA) and cblC deficiency while the benefit for individuals with propionic acidemia and cobalamin‐nonresponsive MMA is less evident due to the high (neonatal) decompensation rate, mortality, and long‐term complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heidelberg University, Medical Faculty of Heidelberg, Center for Child and Adolescent Medicine, Division of Child Neurology and Metabolic Medicine, Heidelberg, Germany.
- University Children's Hospital, Frankfurt, Germany.
- Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center, University of Freiburg, Faculty of Medicine, Freiburg, Germany.
- Department of General Pediatrics, Neonatology, and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
- Children's Hospital Reutlingen, Klinikum am Steinenberg Reutlingen, Reutlingen, Germany.
- Villa Metabolica, Department of Pediatric and Adolescent Medicine, University Medical Center Mainz, Mainz, Germany.
ORCID-Profile: Anna T Reischl-Hajiabadi, Ulrike Mütze
Förderung
- Dietmar Hopp Stiftung
Zitieren
APA
Reischl-Hajiabadi, A. T., Schnabel, E., Gleich, F., Mengler, K., Lindner, M., Burgard, P., Posset, R., Lommer-Steinhoff, S., Grünert, S. C., Thimm, E., Freisinger, P., Hennermann, J. B., Krämer, J., Gramer, G., Lenz, D., Christ, S., Hörster, F., Hoffmann, G. F., Garbade, S. F., …, & Mütze, U. (2024). Outcomes after newborn screening for propionic and methylmalonic acidemia and homocystinurias. Journal of Inherited Metabolic Disease, 47(4), 674-689. https://doi.org/10.1002/jimd.12731
Vancouver
Reischl-Hajiabadi AT, Schnabel E, Gleich F, Mengler K, Lindner M, Burgard P, et al. Outcomes after newborn screening for propionic and methylmalonic acidemia and homocystinurias. Journal of Inherited Metabolic Disease. 2024;47(4):674-689. doi:10.1002/jimd.12731
BibTeX
@article{ReischlHajiabadi2024,
author = {Reischl-Hajiabadi, Anna T and Schnabel, Elena and Gleich, Florian and Mengler, Katharina and Lindner, Martin and Burgard, Peter and Posset, Roland and Lommer-Steinhoff, Svenja and Grünert, Sarah C and Thimm, Eva and Freisinger, Peter and Hennermann, Julia B and Krämer, Johannes and Gramer, Gwendolyn and Lenz, Dominic and Christ, Stine and Hörster, Friederike and Hoffmann, Georg F and Garbade, Sven F and Kölker, Stefan and Mütze, Ulrike},
title = {Outcomes after newborn screening for propionic and methylmalonic acidemia and homocystinurias},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
volume = {47},
number = {4},
pages = {674--689},
doi = {10.1002/jimd.12731}
}
EUVIMED